Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 8;200(5):400–408. doi: 10.1007/s00066-023-02180-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — Univariate analysis using Kaplan–Meier curves with log-rank test for progression-free survival (PFS) and overall survival (OS) based on a oligometastatic disease (OMD) type (metachronous vs. synchronous), b histology (squamous cell cancer vs. nonsquamous cell cancer), c p16 (positive vs. negative), d time to progression (TTP) > 150 days (yes vs. no), e de novo OMD vs. induced OMD, f those who received chemotherapy throughout metastatic disease vs those who did not receive chemotherapy, g those who received immunotherapy (IO)